Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are considered essential for a definite diagnosis, but poor performance and misinterpretation of the results frequently leads to misdiagnosi...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Lancet neurology Ročník 18; číslo 8; s. 784 - 794
Hlavní autori: Bunschoten, Carina, Jacobs, Bart C, Van den Bergh, Peter Y K, Cornblath, David R, van Doorn, Pieter A
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Elsevier Ltd 01.08.2019
Elsevier Limited
Predmet:
Ataxia
Cell adhesion & migration
Corticosteroids
Demyelination
Diagnosis
Genotype & phenotype
Guillain-Barre syndrome
Immunoglobulin G4
Immunoglobulins
Inflammation
Intravenous administration
Magnetic resonance imaging
Medical diagnosis
Motor neurone disease
Nerve conduction
Neuropathy
Phenotypes
Proteins
Ultrasound
ISSN:1474-4422, 1474-4465, 1474-4465
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are considered essential for a definite diagnosis, but poor performance and misinterpretation of the results frequently leads to misdiagnosis. Nerve ultrasound and MRI could be helpful in diagnosis. Whereas typical CIDP is relatively easy to diagnose, atypical variants with distinct phenotypes can be a diagnostic challenge. Intravenous or subcutaneous immunoglobulin, corticosteroids, and plasma exchange are effective treatments, but maintenance treatments are often required for years, and treatment regimens require careful and regular adjustments to avoid undertreatment or overtreatment. Patients who do not improve, or insufficiently improve after treatment, might have specific characteristics related to a distinct disease mechanism caused by immunoglobulin G4 antibodies to nodal or paranodal proteins, and could require alternative treatments. Future studies should focus on curative and individualised treatment regimens to improve the patient's condition and to prevent further nerve damage.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1474-4422
1474-4465
1474-4465
DOI:10.1016/S1474-4422(19)30144-9